HHS Price Forum: Surprisingly Good Context For Pharma Ideas For Regulatory Changes
This article was originally published in RPM Report
The Obama Administration’s public forum to discuss responses to high drug prices sounded like a major threat to innovator companies. But it provided a setting to press for changes in marketing regulation sought by industry for years.
You may also be interested in...
Manufacturer communications with providers and payers could include real-world evidence and pharmacoeconomic information, associations urge.
FDA is joining the government’s bioresponse and defense efforts to develop small, mobile, on-demand manufacturing systems as next-tech solutions to dwindling domestic supply sources for essential drugs.
How should FDA make sure new safety information gets widely disseminated – especially against a history of many communications that have not shown the sustained ability to reach the most active prescribers? The agency got an earful of suggestions from the most recent safety review of the asthma/allergy drug montelukast.